Oruka Therapeutics Inc
ORKAHealthcare|Biotechnology|USA
$86.79
-1.48 (-1.68%)
Tangible Book
$9.64
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07474792 Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | P2 | Recruiting | 160 | RCT, Double-blind | ORKA-002 |
| NCT07090330 ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | P2 | Active | 80 | RCT, Double-blind | ORKA-001 Induction Dose, ORKA-001 Maintenance Dose |
| NCT07290569 Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | P2 | Recruiting | 160 | RCT, Double-blind | ORKA-001 |
| NCT07449702 An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis | Plaque Psoriasis | P2 | Recruiting | 240 | Open-label | ORKA-001 |
| NCT06944379 ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose | Healthy Volunteers | P1 | Active | 24 | RCT, Double-blind | ORKA-002 |
| NCT06698939 ORKA-001 in Healthy Volunteers | Healthy Volunteers | P1 | Completed | 24 | RCT, Double-blind | ORKA-001 |